Advertisement
The reconstruction program looks to create a new Plexur(R) Biocompositemade of allograft bone fibers or particles and utilizes a novel biodegradablepolyurethane to facilitate healing and improve outcomes. This new Plexur(R)Biocomposite will be developed through the collaborative efforts of Dr.Hollinger, Dr. Scott Guelcher at Vanderbilt University, and Osteotech'sscientific team. Osteotech has had a long-standing working relationship withDr. Hollinger and Dr. Guelcher.
Advertisement
Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer,stated, "We are very pleased and proud that our Plexur(R) Technology will beused in this research effort at Vanderbilt University and Carnegie MellonUniversity. The need is great for regenerative solutions to treat serioustraumatic injuries to the skull due to wartime injuries. Our Plexur(R)Technology has the potential to offer new solutions in reconstruction of thecraniofacial region and elsewhere in the body to treat damage from these verydifficult injuries."
Osteotech previously obtained a license from Carnegie Mellon Universityfor the biodegradable polyurethane that is to be used in this program. Thisbiodegradable polyurethane, in combination with Osteotech's Plexur(R)Technology, has been licensed to Vanderbilt University for research purposes.The collaborative research efforts are directed in part, towards developing abiocomposite that has unique characteristics, including high compressive,torsional or bending strength. Osteotech has the rights to any productdeveloped within its current Plexur(R) intellectual property estate and anon-exclusive right to any technology improvements.
The Plexur(R) Technology uses bone tissue for procedure-specific surgicalapplications in combination with a wide variety of polymers. On a world-widebasis, Osteotech controls over 33 patents and over 65 pending patentapplications covering this technology for human and xenograft bone tissue. Formore information about the Plexur(R) Technology or Osteotech's Plexur P(TM) orPlexur M(TM) Biocomposites, please go to the Osteotech website athttp://www.osteotech.com.
The New Jersey Center for Biomaterials is an academic research center atRutgers, The State University of New Jersey. The center links researchuniversities nationwide with industry and government to develop advancedmaterials for tissue repair and replacement, and drug delivery systems.Technology invented at the center is currently being licensed by threecompanies for the development of cardiovascular, ophthalmic and surgicalimplants. For further information regarding the New Jersey Center forBiomaterials, please visit http://www.njbiomaterials.com.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a globalleader in providing OsteoBiologic solutions for regenerative medicine tosupport surgeons and their patients in the repair of the musculoskeletalsystem through the development of innovative therapy-driven products thatalleviate pain, promote biologic healing and restore function. For furtherinformation regarding Osteotech or this press release, please go toOst
